Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia (CLL) Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

ClinicalTrials.gov ID: NCT02141282

Public ClinicalTrials.gov record NCT02141282. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search
ClinicalTrials.gov public records Last synced Oct 18, 2026, 9:35 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 2 Open-Label Study of the Efficacy and Safety of ABT-199 (GDC-0199) in Chronic Lymphocytic Leukemia Subjects With Relapse or Refractory to B-Cell Receptor Signaling Pathway Inhibitor Therapy

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This was an open-label, non-randomized, multicenter, Phase 2 study evaluating the efficacy and safety of ABT-199 in 127 participants with relapsed or refractory chronic lymphocytic leukemia (CLL) after B-cell receptor signaling pathway inhibitors (BCR PI) treatment.

Study identification

NCT ID
NCT02141282
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
AbbVie
Industry
Enrollment
127 participants

Conditions and interventions

Interventions

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 10, 2014 (Actual)
Primary completion
Dec 22, 2021 (Actual)
Completion
Dec 22, 2021 (Actual)
Last update posted
Dec 19, 2022

2014 – 2021

United States locations

U.S. sites
15
U.S. states
10
U.S. cities
13
Facility City State ZIP Site status
Moores Cancer Center at UC San Diego /ID# 128535 La Jolla California 92093 —
University of California, Los Angeles /ID# 127262 Los Angeles California 90095 —
Stanford University School of Med /ID# 126495 Stanford California 94305-2200 —
Georgetown University Hospital /ID# 127261 Washington D.C. District of Columbia 20007 —
Emory Midtown Infectious Disease Clinic /ID# 131249 Atlanta Georgia 30322 —
Northwestern University Feinberg School of Medicine /ID# 126497 Chicago Illinois 60611-2927 —
Beth Israel Deaconess Medical Center /ID# 134509 Boston Massachusetts 02215-5400 —
Dana-Farber Cancer Institute /ID# 126496 Boston Massachusetts 02215 —
Columbia Univ Medical Center /ID# 128536 New York New York 10032-3725 —
New York Presbyterian Hospital Weill Cornell Medical Center /ID# 129648 New York New York 10032-3725 —
Univ Rochester Med Ctr /ID# 130011 Rochester New York 14642 —
The Ohio State University /ID# 127263 Columbus Ohio 43210 —
University of Pennsylvania /ID# 126860 Philadelphia Pennsylvania 19104-5502 —
University of Texas MD Anderson Cancer Center /ID# 126498 Houston Texas 77030 —
University of Utah /ID# 130813 Salt Lake City Utah 84112-5500 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02141282, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 19, 2022 · Synced Oct 18, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT02141282 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →